The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision ...
RARE reports mixed fourth-quarter results, as earnings miss estimates while revenues beat the same. Product sales increase year over year.
Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...
Artificial Kidney Market Report Introduction 2 Artificial Kidney Market Executive Summary 3 Competitive Landscape ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback